Melanie E. Royce

Internal Medicine

Albuquerque, NM 87102

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer.

FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 16, 2025

FDA Approval Summary: Capecitabine Labeling Update under Project Renewal.

FDA Approval Summary: Capecitabine Labeling Update under Project Renewal.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 30, 2024

US Food and Drug Administration Expanded Adjuvant Indication of Abemaciclib in High-Risk Early Breast Cancer.

US Food and Drug Administration Expanded Adjuvant Indication of Abemaciclib in High-Risk Early Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 27, 2023

FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer.

FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 27, 2022

FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer.

FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 09, 2021

E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.

E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 06, 2021

U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review.

U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 04, 2021

U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review.

U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 04, 2021

Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis.

Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis.

Journal: The Lancet. Oncology

Published: June 10, 2021

Obesity and survival among a cohort of breast cancer patients is partially mediated by tumor characteristics.

Obesity and survival among a cohort of breast cancer patients is partially mediated by tumor characteristics.

Journal: NPJ breast cancer

Published: April 23, 2019

Temporal trends in breast cancer survival by race and ethnicity: A population-based cohort study.

Temporal trends in breast cancer survival by race and ethnicity: A population-based cohort study.

Journal: PloS one

Published: January 02, 2019

Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial.

Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial.

Journal: JAMA oncology

Published: September 08, 2018

Showing 1-12 of 30

Last Updated: 09/26/2026